Clinical Effects for Patients with Recurrent Advanced Non-small Cell Lung Cancer Treated with Icotinib Hydrochloride
Background and objective Icotinib hydrochloride is the third single target EGFR-TKI used in clinical treatment of advanced non-small cell lung cancer (NSCLC). Clinical research reports on its efficacy and survival in patients with Recurrent Advanced NSCLC are still little.The aim of this study is to...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | zho |
| Published: |
Chinese Anti-Cancer Association; Chinese Antituberculosis Association
2013-05-01
|
| Series: | Chinese Journal of Lung Cancer |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.3779/j.issn.1009-3419.2013.05.05 |
| _version_ | 1811259520020643840 |
|---|---|
| author | Jingying NONG Na QIN Jinghui WANG Xinjie YANG Hui ZHANG Yuhua WU Jialin LV Quan ZHANG Shucai ZHANG |
| author_facet | Jingying NONG Na QIN Jinghui WANG Xinjie YANG Hui ZHANG Yuhua WU Jialin LV Quan ZHANG Shucai ZHANG |
| author_sort | Jingying NONG |
| collection | DOAJ |
| description | Background and objective Icotinib hydrochloride is the third single target EGFR-TKI used in clinical treatment of advanced non-small cell lung cancer (NSCLC). Clinical research reports on its efficacy and survival in patients with Recurrent Advanced NSCLC are still little.The aim of this study is to evaluate the efficacy and survival of Icotinib hydrochloride for patients with advanced non-small cell lung cancer who failed to previous chemotherapy and explore the association of clinical features with the efficacy and survival. Methods The clinical data of 60 NSCLC patients referred to the Beijing Chest Hospital, Capital Medical University from March 2009 to July 2012 were retrospectively analyzed. Results The overall response rate (ORR) was 45.0% and the disease control rate (DCR) was 80.0%. The median progression-free survival (PFS) time was 6.7 months. RR and PFS in female were superior to male (P=0.014, 0.013, respectively). RR, DCR in 2nd-line subgroup were superior to ≥3rd-line subgroup (P=0.020, 0.024, respectively). RR, DCR and PFS in EGFR mutation carriers were significantly superior to wild-type patients (P=0.006, <0.001, 0.002, respectively) . There was no statistical difference in RR and PFS between those age <65 and ≥65 or PS<2 and PS≥2. There was no statistical difference in RR and DCR between exon 19 deletion and exon 21 mutations, while the former had much longer PFS (P=0.020). EGFR mutation and exon 19 deletion are the independent prognostic factors to significantly improve the PFS (P=0.009, 0.012, respectively). The side effects were generally mild and consisted of rash and diarrhea. Conclusion Icotinib hydrochloride is effective especially in EGFR mutation carriers and well tolerated in patients with recurrent advanced non-small-cell lung cancer. |
| first_indexed | 2024-04-12T18:32:49Z |
| format | Article |
| id | doaj.art-458b66d1bf2342ab8a478083a0661dc7 |
| institution | Directory Open Access Journal |
| issn | 1009-3419 1999-6187 |
| language | zho |
| last_indexed | 2024-04-12T18:32:49Z |
| publishDate | 2013-05-01 |
| publisher | Chinese Anti-Cancer Association; Chinese Antituberculosis Association |
| record_format | Article |
| series | Chinese Journal of Lung Cancer |
| spelling | doaj.art-458b66d1bf2342ab8a478083a0661dc72022-12-22T03:21:01ZzhoChinese Anti-Cancer Association; Chinese Antituberculosis AssociationChinese Journal of Lung Cancer1009-34191999-61872013-05-0116524024510.3779/j.issn.1009-3419.2013.05.05Clinical Effects for Patients with Recurrent Advanced Non-small Cell Lung Cancer Treated with Icotinib HydrochlorideJingying NONGNa QINJinghui WANGXinjie YANGHui ZHANGYuhua WUJialin LVQuan ZHANGShucai ZHANGBackground and objective Icotinib hydrochloride is the third single target EGFR-TKI used in clinical treatment of advanced non-small cell lung cancer (NSCLC). Clinical research reports on its efficacy and survival in patients with Recurrent Advanced NSCLC are still little.The aim of this study is to evaluate the efficacy and survival of Icotinib hydrochloride for patients with advanced non-small cell lung cancer who failed to previous chemotherapy and explore the association of clinical features with the efficacy and survival. Methods The clinical data of 60 NSCLC patients referred to the Beijing Chest Hospital, Capital Medical University from March 2009 to July 2012 were retrospectively analyzed. Results The overall response rate (ORR) was 45.0% and the disease control rate (DCR) was 80.0%. The median progression-free survival (PFS) time was 6.7 months. RR and PFS in female were superior to male (P=0.014, 0.013, respectively). RR, DCR in 2nd-line subgroup were superior to ≥3rd-line subgroup (P=0.020, 0.024, respectively). RR, DCR and PFS in EGFR mutation carriers were significantly superior to wild-type patients (P=0.006, <0.001, 0.002, respectively) . There was no statistical difference in RR and PFS between those age <65 and ≥65 or PS<2 and PS≥2. There was no statistical difference in RR and DCR between exon 19 deletion and exon 21 mutations, while the former had much longer PFS (P=0.020). EGFR mutation and exon 19 deletion are the independent prognostic factors to significantly improve the PFS (P=0.009, 0.012, respectively). The side effects were generally mild and consisted of rash and diarrhea. Conclusion Icotinib hydrochloride is effective especially in EGFR mutation carriers and well tolerated in patients with recurrent advanced non-small-cell lung cancer.http://dx.doi.org/10.3779/j.issn.1009-3419.2013.05.05IcotinibLung neoplasmsEfficacy |
| spellingShingle | Jingying NONG Na QIN Jinghui WANG Xinjie YANG Hui ZHANG Yuhua WU Jialin LV Quan ZHANG Shucai ZHANG Clinical Effects for Patients with Recurrent Advanced Non-small Cell Lung Cancer Treated with Icotinib Hydrochloride Chinese Journal of Lung Cancer Icotinib Lung neoplasms Efficacy |
| title | Clinical Effects for Patients with Recurrent Advanced Non-small Cell Lung Cancer Treated with Icotinib Hydrochloride |
| title_full | Clinical Effects for Patients with Recurrent Advanced Non-small Cell Lung Cancer Treated with Icotinib Hydrochloride |
| title_fullStr | Clinical Effects for Patients with Recurrent Advanced Non-small Cell Lung Cancer Treated with Icotinib Hydrochloride |
| title_full_unstemmed | Clinical Effects for Patients with Recurrent Advanced Non-small Cell Lung Cancer Treated with Icotinib Hydrochloride |
| title_short | Clinical Effects for Patients with Recurrent Advanced Non-small Cell Lung Cancer Treated with Icotinib Hydrochloride |
| title_sort | clinical effects for patients with recurrent advanced non small cell lung cancer treated with icotinib hydrochloride |
| topic | Icotinib Lung neoplasms Efficacy |
| url | http://dx.doi.org/10.3779/j.issn.1009-3419.2013.05.05 |
| work_keys_str_mv | AT jingyingnong clinicaleffectsforpatientswithrecurrentadvancednonsmallcelllungcancertreatedwithicotinibhydrochloride AT naqin clinicaleffectsforpatientswithrecurrentadvancednonsmallcelllungcancertreatedwithicotinibhydrochloride AT jinghuiwang clinicaleffectsforpatientswithrecurrentadvancednonsmallcelllungcancertreatedwithicotinibhydrochloride AT xinjieyang clinicaleffectsforpatientswithrecurrentadvancednonsmallcelllungcancertreatedwithicotinibhydrochloride AT huizhang clinicaleffectsforpatientswithrecurrentadvancednonsmallcelllungcancertreatedwithicotinibhydrochloride AT yuhuawu clinicaleffectsforpatientswithrecurrentadvancednonsmallcelllungcancertreatedwithicotinibhydrochloride AT jialinlv clinicaleffectsforpatientswithrecurrentadvancednonsmallcelllungcancertreatedwithicotinibhydrochloride AT quanzhang clinicaleffectsforpatientswithrecurrentadvancednonsmallcelllungcancertreatedwithicotinibhydrochloride AT shucaizhang clinicaleffectsforpatientswithrecurrentadvancednonsmallcelllungcancertreatedwithicotinibhydrochloride |